Pacific GeneTech
Pacific GeneTech develops and commercializes next-generation vaccines and biologics targeting areas of high unmet need in food safety and animal health. Their proprietary platforms, Aegis and Hercules, enable broad-spectrum protection and enhanced vaccine efficacy. The company collaborates globally, licensing its vaccines and adjuvants for use in various animal species and human applications, with a focus on innovative, cost-effective solutions that contribute to food safety, reduce antibiotic resistance, and support sustainable development.
Industries
Nr. of Employees
small (1-50)
Pacific GeneTech
14352 E Highway 12, Rogers, AR 72756 USA
Products
Recombinant microbial vector vaccine platform (Aegis)
A platform that uses recombinant bacterial and yeast vectors to present conserved antigens and immunopotentiators on vector surfaces for cross-protective vaccine constructs suitable for live or inactivated formats and oral or injectable delivery.
Universal mannosylated chitosan adjuvant/delivery system (Hercules)
A modified chitosan-based adjuvant designed to enhance mucosal immunity, direct antigens to antigen-presenting cells, and improve efficacy of orally and injectable inactivated and DNA vaccines.
Inactivated oral Eimeria (coccidiosis) vaccine for poultry
An inactivated oral vaccine formulation for multiple Eimeria species administered via spray or drinking water, developed using a recombinant vector platform with an adjuvant delivery system; positioned as a cross-protective alternative to live oocyst vaccines.
Oral cross-protective enteric vaccine for swine (Salmonella / E. coli)
A live attenuated oral vaccine based on a conserved antigen to provide cross-protection against Salmonella and pathogenic E. coli strains, evaluated for reduction of fecal shedding and improvement in growth performance.
Recombinant microbial vector vaccine platform (Aegis)
A platform that uses recombinant bacterial and yeast vectors to present conserved antigens and immunopotentiators on vector surfaces for cross-protective vaccine constructs suitable for live or inactivated formats and oral or injectable delivery.
Universal mannosylated chitosan adjuvant/delivery system (Hercules)
A modified chitosan-based adjuvant designed to enhance mucosal immunity, direct antigens to antigen-presenting cells, and improve efficacy of orally and injectable inactivated and DNA vaccines.
Inactivated oral Eimeria (coccidiosis) vaccine for poultry
An inactivated oral vaccine formulation for multiple Eimeria species administered via spray or drinking water, developed using a recombinant vector platform with an adjuvant delivery system; positioned as a cross-protective alternative to live oocyst vaccines.
Oral cross-protective enteric vaccine for swine (Salmonella / E. coli)
A live attenuated oral vaccine based on a conserved antigen to provide cross-protection against Salmonella and pathogenic E. coli strains, evaluated for reduction of fecal shedding and improvement in growth performance.
Services
Licensing vaccine and adjuvant technology to global and regional partners for scale-up, registration and distribution.
Regional manufacturing and supply of adjuvant material through joint-venture manufacturing partnerships to serve local markets.
Collaborative discovery and translational programs with universities and industry partners to advance vaccine candidates from discovery to preclinical proof-of-concept.
Licensing vaccine and adjuvant technology to global and regional partners for scale-up, registration and distribution.
Regional manufacturing and supply of adjuvant material through joint-venture manufacturing partnerships to serve local markets.
Collaborative discovery and translational programs with universities and industry partners to advance vaccine candidates from discovery to preclinical proof-of-concept.
Expertise Areas
- Vaccine research and development
- Adjuvant formulation and mucosal immunity
- Preclinical animal trial design and execution
- Bioprocessing and fermentation manufacturing
Key Technologies
- Recombinant bacterial vectors
- Yeast expression vectors
- Mannosylated chitosan adjuvant
- Oral/nasal vaccine delivery
News & Updates
Development of the new US headquarters in Northwest Arkansas, including a manufacturing suite and R&D laboratory, expected to be completed in Q4 2023.
Recent trial results show the vaccine performs better than a leading commercial vaccine, with rapid reduction of fecal shedding and improved weight gain.
Safety trial results show Hercules adjuvant does not cause adverse reactions in rainbow trout, with further challenge trials planned.
Funding will accelerate development of the Aegis platform, expand US facilities, and support vaccine licensing.
New manufacturing and business development in Arkansas for vaccines against pathogens like Salmonella, Eimeria, and Avian influenza.
Trial conducted at Southern Research Poultry shows the vaccine performs well against Eimeria species, with potential to be the only inactivated Eimeria vaccine on the market.
Development of the new US headquarters in Northwest Arkansas, including a manufacturing suite and R&D laboratory, expected to be completed in Q4 2023.
Recent trial results show the vaccine performs better than a leading commercial vaccine, with rapid reduction of fecal shedding and improved weight gain.
Safety trial results show Hercules adjuvant does not cause adverse reactions in rainbow trout, with further challenge trials planned.
Funding will accelerate development of the Aegis platform, expand US facilities, and support vaccine licensing.
New manufacturing and business development in Arkansas for vaccines against pathogens like Salmonella, Eimeria, and Avian influenza.
Trial conducted at Southern Research Poultry shows the vaccine performs well against Eimeria species, with potential to be the only inactivated Eimeria vaccine on the market.